Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Completed 77Terminated 22Recruiting 11Unknown 8Not yet recruiting 5Active not recruiting 5Withdrawn 3

Sponsor Class

NIH 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 9CNS 6Gynecologic 5Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Ovarian Neoplasms 3Fallopian Tube Neoplasms 3Uterine Cervical Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Mucinous Adenocarcinoma 1

Interventions

pembrolizumab 45Paclitaxel 45Carboplatin 39Magnetic Resonance Spectroscopy 28olaparib 27Specimen Handling 26Cisplatin 24Bevacizumab 20Nivolumab 18Taxes 17Biopsy 16Gemcitabine 13Cyclophosphamide 13durvalumab 12Immunoglobulin G 11Doxorubicin 11Disulfides 11Surveys and Questionnaires 10niraparib 9liposomal doxorubicin 9dostarlimab 9Radiotherapy 8Brachytherapy 8lenvatinib 7fludarabine 7atezolizumab 7Letrozole 7Docetaxel 7cediranib 6Platinum 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × Topotecan × Gynecologic × Clear all
NCT06619236 2026-06-02

RAINFOL-02

Genmab

Phase 3 Active not recruiting
448 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

NCT06459180 2026-05-27

TroFuse-020

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
686 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT01012817 2026-04-29

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
88 enrolled 23 charts
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT02502266 2026-04-29

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
582 enrolled 21 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡